vs
Side-by-side financial comparison of Inhibikase Therapeutics, Inc. (IKT) and OLB GROUP, INC. (OLB). Click either name above to swap in a different company.
OLB GROUP, INC. is the larger business by last-quarter revenue ($1.8M vs $1.0M, roughly 1.7× Inhibikase Therapeutics, Inc.). OLB GROUP, INC. runs the higher net margin — -83.7% vs -1223.3%, a 1139.6% gap on every dollar of revenue.
Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on developing novel disease-modifying therapies for neurodegenerative disorders including Parkinson's disease. It advances pipeline candidates through preclinical and clinical studies to address unmet medical needs and improve patient outcomes worldwide.
OLB Group, Inc. is a global financial technology provider offering omnichannel payment processing solutions, e-commerce enablement tools, and digital banking services for small and medium-sized enterprises across North America, Europe, and key Asia-Pacific markets. Its core segments include merchant services, crypto payment integration, and cloud-based business management platforms.
IKT vs OLB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0M | $1.8M |
| Net Profit | $-12.7M | $-1.5M |
| Gross Margin | — | — |
| Operating Margin | -1323.3% | -83.7% |
| Net Margin | -1223.3% | -83.7% |
| Revenue YoY | — | -35.2% |
| Net Profit YoY | -5.0% | 67.5% |
| EPS (diluted) | $-0.10 | $-0.48 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0M | $1.8M | ||
| Q3 25 | $0 | $2.3M | ||
| Q2 25 | $0 | $2.3M | ||
| Q1 25 | $0 | $2.3M | ||
| Q4 24 | $0 | $2.7M | ||
| Q3 24 | $0 | $3.1M | ||
| Q2 24 | $0 | $3.5M | ||
| Q1 24 | $0 | $3.5M |
| Q4 25 | $-12.7M | $-1.5M | ||
| Q3 25 | $-11.9M | $-1.2M | ||
| Q2 25 | $-9.9M | $-2.1M | ||
| Q1 25 | $-13.7M | $-1.1M | ||
| Q4 24 | $-12.1M | $-4.6M | ||
| Q3 24 | $-5.8M | $-1.6M | ||
| Q2 24 | $-5.0M | $-2.6M | ||
| Q1 24 | $-4.6M | $-2.4M |
| Q4 25 | -1323.3% | -83.7% | ||
| Q3 25 | — | -49.1% | ||
| Q2 25 | — | -74.8% | ||
| Q1 25 | — | -36.6% | ||
| Q4 24 | — | -166.0% | ||
| Q3 24 | — | -52.9% | ||
| Q2 24 | — | -74.3% | ||
| Q1 24 | — | -82.6% |
| Q4 25 | -1223.3% | -83.7% | ||
| Q3 25 | — | -50.8% | ||
| Q2 25 | — | -93.7% | ||
| Q1 25 | — | -46.9% | ||
| Q4 24 | — | -167.1% | ||
| Q3 24 | — | -52.9% | ||
| Q2 24 | — | -75.2% | ||
| Q1 24 | — | -67.8% |
| Q4 25 | $-0.10 | $-0.48 | ||
| Q3 25 | $-0.13 | $-0.13 | ||
| Q2 25 | $-0.11 | $-0.66 | ||
| Q1 25 | $-0.15 | $-0.47 | ||
| Q4 24 | $0.88 | $-3.55 | ||
| Q3 24 | $-0.65 | $-0.92 | ||
| Q2 24 | $-0.66 | $-1.49 | ||
| Q1 24 | $-0.73 | $-0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $218.3M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $172.9M | $4.6M |
| Total Assets | $181.2M | $12.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $218.3M | — | ||
| Q3 25 | $39.1M | — | ||
| Q2 25 | $9.9M | — | ||
| Q1 25 | $19.7M | $29.3K | ||
| Q4 24 | $138.6M | $27.4K | ||
| Q3 24 | $2.3M | $41.3K | ||
| Q2 24 | $4.9M | $53.3K | ||
| Q1 24 | $7.4M | $3.3K |
| Q4 25 | $172.9M | $4.6M | ||
| Q3 25 | $72.9M | $5.3M | ||
| Q2 25 | $80.1M | $6.4M | ||
| Q1 25 | $85.7M | $2.3M | ||
| Q4 24 | $94.9M | $3.2M | ||
| Q3 24 | $-530.6K | $6.7M | ||
| Q2 24 | $5.1M | $8.3M | ||
| Q1 24 | $6.8M | $11.0M |
| Q4 25 | $181.2M | $12.3M | ||
| Q3 25 | $79.6M | $12.2M | ||
| Q2 25 | $88.9M | $12.4M | ||
| Q1 25 | $94.3M | $12.5M | ||
| Q4 24 | $98.6M | $12.7M | ||
| Q3 24 | $4.4M | $15.9M | ||
| Q2 24 | $8.8M | $16.6M | ||
| Q1 24 | $11.1M | $18.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.5M | $-1.3M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-7.5M | $-1.3M | ||
| Q3 25 | $-10.6M | $-115.5K | ||
| Q2 25 | $-5.6M | $-1.0M | ||
| Q1 25 | $-4.1M | $-155.8K | ||
| Q4 24 | $-5.3M | $-2.6M | ||
| Q3 24 | $-4.9M | $-376.7K | ||
| Q2 24 | $-5.1M | $-785.5K | ||
| Q1 24 | $-3.9M | $-424.7K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-4.1M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IKT
Segment breakdown not available.
OLB
| Transaction And Processing Fees | $1.7M | 94% |
| Other | $99.2K | 6% |
